News on medical imaging technologies and applications.
With the acquisition, Luminex has expanded its offering of flow-based detection systems and broadened direct interactions with researchers conducting cellular analysis.
The deal is expected to close by the end of 2018 and to contribute between $40 million and $50 million in revenues to Luminex in 2019.
The assay will combine the company's CytoSort assay with its automated AIR system for imaging, sorting, and isolating single cells and small colonies.
